Predemption

7- $TRVI has a $18 preice tgt from one analyst

Long
NASDAQ:TRVI   Trevi Therapeutics, Inc.
Low float under 3M, one analyst has a 52-week buy rating of $18

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.